New drugs and combinations in the palliative treatment of colon and rectal cancer

European Journal of Surgical Oncology

Volumn 27, Issue 6, 2001, Pages 595-600

  Beretta, G D ^a   Pessi, M A ^a   Poletti, P ^a   Mosconi, S ^a   Labianca, R ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Chemotherapy; Colorectal cancer

Indexed keywords

5 ETHYNYLURACIL; ANTINEOPLASTIC AGENT; CAPECITABINE; DNA TOPOISOMERASE INHIBITOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; NEW DRUG; ORZEL; OXALIPLATIN; PLATINUM DERIVATIVE; RALTITREXED; THYMIDYLATE SYNTHASE INHIBITOR;

ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; HUMAN; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; SYMPTOM; VOMITING;

EID: 0034857599     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.2001.1128     Document Type: Article

References (31)

1. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer
2. Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer
3. Should we consider the weekly (w) chemotherapy (CT) with fluorouracil (F)+ racemin folinic acid (f) a standard treatment for advanced/metastatic carcinoma of the digestive tract (DTC) in elderly patients (pts)?
4. Expectancy or primary chemotherapy in patients in patients with advanced asyntomatic colorectal cancer: A randomized trial
5. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
6. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
7. High-versus low dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A GISCAD phase III study
8. Fluorouracil in colorectal cancer - A tale of two drugs: Implications for biochemical modulation
9. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
10. A double-blind comparison of intensive course 5-fluorouracil by oral versus intravenous route in the treatment of colorectal carcinoma
11. Capecitabine: An orally available fluoropyrimidine with tumor selective activity
12. Antitumor activity of Capecitabine against fluorouracil sensitive and resistant tumors
13. A phase I study of continuous twice daily treatment with capecitabine in patients with advanced and/or metastatic solid tumours
14. Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma
15. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil
16. Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin and cisplatin therapy in patients with advanced colorectal cancer
17. Final results of a randomized trail comparing tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
18. Topoisomerase I inhibitors in the treatment of colorectal cancer
19. Irinotecan (CPT-II) therapy for patients with previously treated metastatic colorectal cancer: Overall results of FDA-reviewed pivotal US clinical trials
20. Clinical activity and benefit of irinotecan (CPT-II) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
21. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
22. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
23. Weekly irinotecan (CPT-II), leucovorin and fluorouracil is superior to daily × 5 leucovorin + 5-FU in patients with previously untreated metastatic colorectal cancer
24. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
25. Oxaliplatin: A new therapeutic option in colorectal cancer
26. A randomized trial of leucovorin (LV) and 5fluorouracil (5FU) with or without oxaliplatin in advanced colorectal cancer (CRC)
27. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
28. Long-term survival of patients with unresectable colorectal cancer liver metatases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery
29. A prospective randomized trial of protracted venuous infusion of 5-fluorouracil with or without mitomycin C in advanced colorectal cancer
30. Tomudex (raltitrexed) plus oxaliplatin as first-line chemotherapy in metastatic colorectal cancer (MCRC): A promising combination
31. Combination of oxaliplatin (L-OHP) plus irinotecan (CPT-II) in patients with gastrointestinal tumors: Results of two independent phase I studies with pharmacokinetics